Pharma

Saunders Seen As Key Man in Pfizer-Allergan Mashup

Saunders Seen As Key Man in Pfizer-Allergan Mashup

By Tom Salemi | December 2, 2015

Last week, Pfizer and Allergan executives gave us a lot to chew on over the Thanksgiving weekend. The $160 billion combination will create the world’s…

Read More

Saunders Promises ‘Greater Impact’ on Ophthalmology

By Rich Kirkner | November 24, 2015

With the planned combination of Pfizer and Allergan to create the world’s largest pharmaceutical company, Brent Saunders, a key player in two significant acquisitions of…

Read More
A Record-setting OIS

A Record-Setting OIS

By Tom Salemi | November 19, 2015

Last week’s Ophthalmology Innovation Summit drew nearly 1,000 attendees to Las Vegas’ Planet Hollywood hotel, marking the largest OIS event we’ve held yet. The size…

Read More
Ophthalmology Innovation Summit Gives Nod to Successful Public Start-ups

Ophthalmology Innovation Summit Gives Nod to Successful Public Start-ups

By Tom Salemi | November 12, 2015

Largest ever gathering will showcase recent IPO Companies, early stage companies and speech by Allergan’s CEO LAS VEGAS, NV (PRWEB) NOVEMBER 12, 2015 The seventh…

Read More
Biggest OIS Ever Set to Deliver News & Insights

Biggest OIS Ever Set to Deliver News & Insights

By Tom Salemi | November 11, 2015

The maturation and advance of the ophthalmology sector will be fully evident tomorrow as we host the largest Ophthalmology Innovation Summit in its seven-year history.…

Read More
Transcend’s Move Toward PMA

Transcend’s Move Toward PMA

By Tom Salemi | October 28, 2015

Well, the MIGs market could get a little more crowded. This week, Transcend Medical announced it had submitted the final module of its PMA application…

Read More
FDA Making the Rounds in Ophthalmology

FDA Making the Rounds in Ophthalmology

By Tom Salemi | October 21, 2015

Over the past week, news about the FDA has been flooding the inboxes of ophthalmology watchers. The most notable news came Shire plc. The regulatory…

Read More
Precision Medicine Gets a Boost & Ophthalmology is Ready

Precision Medicine Gets a Boost & Ophthalmology is Ready

By Rich Kirkner | October 14, 2015

Precision medicine got a boost in mid-September when National Institutes of Health (NIH) advisory committee released a framework for building a cohort of 1 million…

Read More
Gene Therapies Move One Step Closer to Reality

Gene Therapies Move One Step Closer to Reality

By Michelle Dalton | October 9, 2015

Positive top-line results from a pivotal Phase III study may result in the first gene therapy to win U.S. regulatory approval, and sent shares of…

Read More
How Could the 21st Century Cures Act Aid Innovation?

How Could the 21st Century Cures Act Aid Innovation?

By Rich Kirkner | August 21, 2015

There’s more to the 21st Century Cures Act, which passed the full House of Representatives with overwhelming bipartisan support, than $9 billion in new funding…

Read More
Newer glaucoma medication classes about to be a reality?

Newer glaucoma medication classes about to be a reality?

By Tom Salemi | August 13, 2015

While our podcast this week examines the rise of Glaukos and the MIGs market, contributor Michelle Dalton presents a State of the Glaucoma Drugs address.…

Read More
Q&A with Shire’s Robert Dempsey

Q&A with Shire’s Robert Dempsey

By Tom Salemi | August 6, 2015

Shire this week announced plans to acquire Foresight Biotherapeutics for $300 million. Robert Dempsey, Shire’s vice president and head of the company’s ophthalmic unit, kindly…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.